Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics Credited With Helping Zeneca Make Rapid Progress

Premium

ALDERLEY EDGE, UK--Zeneca Pharmaceuticals here has credited bioinformatics with a significant role in the company's recent success. Investments in bioinformatics, gene discovery, and human genetics have helped the firm convert raw genomic data into drug targets quickly, resulting in a current slate of 87 development projects, including 26 for new compounds, and plans to increase the company's research output. The comments came from company officials, including CEO Tom McKillop and Richard Auty, research and development director, in a meeting last week with analysts and investors.

They also noted that Zeneca has been enhancing its genomics capabilities through collaborations with such organizations as Incyte Pharmaceuticals, Molecular Dynamics, and Oxford University. The company's research output is set to double over the next five years, Zeneca claimed.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.